Chronic Pain Management with Opioids: Prevention of Misuse, Abuse and Diversion
(Satellite Dinner Meeting)
Release Date: December 2007
Expiration Date: December 31, 2009
Sponsored by the Dannemiller Memorial Educational Foundation
This educational activity is made possible by an educational grant from Alpharma Pharmaceuticals LLC.
This presentation was recorded in Chicago on October 4, 2007 ( Satellite Dinner Meeting).
Topics:
Rational Opioid Prescribing
Controlled Substances and the Law
Practical Issues in Pain Management
Faculty
Bill H. McCarberg, M.D., FABPM
Founder
Chronic Pain Management Program
Kaiser Permanente San Diego
Assistant Clinical Professor (voluntary)
University of California, San Diego
San Diego, California
Ben A. Rich, JD, PhD
Professor and School of Medicine
Alumni Association Endowed Chair of Bioethics
Department of Internal Medicine
Department of Anesthesiology & Pain Medicine
University of California, Davis School of Medicine
Sacramento, California
Steven P. Stanos, D.O.
Medical Director
Chronic Pain Care Center
Rehabilitation Institute of Chicago
Clinical Instructor
Department of Physical Medicine and Rehabilitation
Northwestern University Medical School
Feinberg School of Medicine
Chicago, Illinois
Statement of Need:
The effectiveness of opioids for chronic pain is unchallenged, but issues of potential dependence and abuse, as well as social legal concerns, have rendered their use in chronic non-malignant pain controversial. Under treatment of chronic pain persists despite the availability of pharmaceuticals and other therapies that are effective for the management of pain. Physicians and other healthcare providers are sometimes reluctant to prescribe appropriate pain medications because of the perceived danger of misuse, abuse and diversion of these drugs. Effective strategies exist that can allow pain sufferers to be provided with the effective pain management they need while minimizing abuse and misuse potential. It is imperative that the vast audience of healthcare professionals who treat patients in pain be provided with this information on the legal, ethical and appropriate prescribing of opioids for chronic pain. The purpose of this activity is to provide participants with a comprehensive update of the problems associated with the prescribing of opioids from both the physician and patient perspective.
- Balance patients’ needs with current regulatory requirements.
- Identify and treat appropriate candidates for opioid therapy.
- Address legal and regulatory issues associated with the dispensing of opioid analgesics, to include statutory and regulatory requirements.
Intended Audience:
This online activity is intended for physicians, physician assistants, pharmacists, nurse practitioners, and nurses.
Learning Objectives:
- Recognize rational approaches to opioid prescribing.
- Discuss current issues relating to pain and the law.
- List some of the new technologies and strategies for delivering abuse-resistant opioids.
Accreditation Statement:
The Dannemiller Memorial Educational Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statements:
The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation:
This activity should take approximately 2 hours to complete. The participant should, in order, read the objectives and other introductory CME information, review the slides and listen to the accompanying audio, complete the registration form, post-test, and evaluation form. The evaluation form provides each participant the opportunity to comment on the extent to which educational objectives were met, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his or her views on future educational needs. To access the registration form and post-test, click on the “CME Post-Test” button on the final slide in the presentation. To receive credit for this activity, follow the instructions provided on the post-test. This credit is valid through December 31, 2009. No credit will be given after this date. There is no fee associated with this CME activity.
In the event you are unable to print the certificate, please submit the post-test and then e-mail editor@dannemiller.com a certificate will be mailed within 2 weeks.
Disclosure Information:
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), the Dannemiller Foundation requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.
The faculty reported the following:
Dr. McCarberg discloses that he is a speaker for Alpharma Pharmaceuticals LLC, Eli Lilly and Company, Endo Pharmaceuticals, Merck and Company Inc., Pfizer Pharmaceutical Company, PriCara, and Purdue Pharma LP.
Dr. Rich discloses that he is a speaker for Pharmacom and on the consultant/advisory board for Alpharma Pharmaceuticals LLC.
Dr. Stanos discloses that he is a speaker and on the consultant/advisory board for Alpharma Pharmaceuticals LLC, Cephalon Inc., Endo Pharmaceuticals, Ortho-McNeil Inc., and Pfizer Pharmaceutical Company.
The Dannemiller Foundation staff that was involved in the development of this activity has no financial relationships with any commercial interests that are relevant to this activity. To resolve identified conflicts of interest, the educational content was fully peer reviewed by a physician member of the Dannemiller Clinical Control Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based and commercial balanced.
Off-label Statement:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Disclaimer Statement:
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the Dannemiller Memorial Educational Foundation or Alpharma Pharmaceuticals LLC. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
For questions regarding the content of this activity and technical assistance, contact Dannemiller Memorial Educational Foundation, accredited provider for this CME activity, at editor@dannemiller.com.
» Click Here To Begin
|